To Whom It May Concern:

Company Name: Taisho Pharmaceutical Holdings Co., Ltd.
Head Office: 3-24-1, Takada, Toshima-ku, Tokyo
Representative: Akira Uehara, President and CEO
(First Section of TSE: Code 4581)
Contact: Takashi Shibata, General Manager
Corporate Communications
(Tel: +81-3-3985-1115)

Acquisition of Manufacturing and Marketing Approval in Japan for the Transdermal
Anti-inflammatory Analgesic Patch Formulation LOQOA® Tape

Taisho Pharmaceutical Holdings Co., Ltd. has announced that its consolidated subsidiary Taisho Pharmaceutical Co., Ltd. (“Taisho Pharmaceutical”) [Head Office: Toshima-ku, Tokyo, President: Shigeru Uehara] today received manufacturing and marketing approval for the transdermal anti-inflammatory analgesic patch formulation LOQOA® Tape (Development Code: TT-063, hereinafter “LOQOA® Tape”) from the Ministry of Health, Labour and Welfare for the indication and usage of “the treatment of osteoarthritis pain and inflammation.” LOQOA® Tape was created by Taisho Pharmaceutical Holdings Co., Ltd.’s consolidated subsidiary TOKUHON Corporation (“TOKUHON”) [Head Office: Toshima-ku, Tokyo; President: Jun-ichi Fukudome], and was co-developed by Taisho Pharmaceutical and TOKUHON in Japan.

LOQOA® Tape is a non-steroidal anti-inflammatory drug (NSAID) patch formulation containing the active ingredients S-flurbiprofen, which is the active form of flurbiprofen, and mentha oil. The patch formulation is designed to provide enhanced drug delivery to the lesion area. In clinical trials, LOQOA® Tape was found to demonstrate good efficacy and a strong safety profile in connection with osteoarthritis.

Osteoarthritis is a chronic degenerative disease of the joints, mainly involving degeneration and abrasion of joint cartilage. Approximately 30% of osteoarthritis patients show symptoms of pain. Considering that pain is a major cause of reduced quality of life (QOL), there are high hopes for the development of powerful patch formulations that possess an anti-inflammatory analgesic action.

LOQOA® Tape is scheduled to be co-marketed in Japan by Taisho Pharmaceutical Holdings Co., Ltd.’s consolidated subsidiary Taisho Toyama Pharmaceutical Co., Ltd. (“Taisho Toyama Pharmaceutical”) [Head Office: Toshima-ku, Tokyo; President Kenichi Fujita] and Teijin Pharma Limited (“Teijin Pharma”) [Head Office: Chiyoda-ku, Tokyo; President: Hiroshi Uno].

Through the marketing of the transdermal anti-inflammatory analgesic patch formulation LOQOA® Tape, Taisho Pharmaceutical seeks to provide many more patients with a new treatment option for osteoarthritis pain and inflammation.

Outline of Approval

<table>
<thead>
<tr>
<th>Product name</th>
<th>LOQOA® Tape</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic name</td>
<td>S-flurbiprofen, mentha oil</td>
</tr>
<tr>
<td>Indication and usage</td>
<td>Treatment of osteoarthritis pain and inflammation</td>
</tr>
<tr>
<td>Dosage and administration</td>
<td>Apply to the lesion area once daily. Do not apply more than two patches simultaneously.</td>
</tr>
<tr>
<td>Ingredients and concentration</td>
<td>40 mg of S-flurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per 10 cm x 14 cm patch</td>
</tr>
</tbody>
</table>